Shares of nano-cap biotech Aikido Pharma Inc (NASDAQ: AIKI), are ripping higher following an announcement concerning worldwide licensing of an antiviral platform.Aikido said it has exercised the option to license from the University of Maryland Baltimore, the broad-spectrum antiviral platform, which is a broadly acting pan-viral inhibitory compound with efficacy against multiple viral pathogens.The technology will inhibit replication of multiple viruses, including influenza virus, SARS-COV, MERS-COV, ebola virus and Marburg virus, it added.The execution of the initial option agreement was announced by Aikido, which was then known as Spherix Pharma, in early March."We continue to vet the technology we optioned, but this antiviral drug platform technology we've licensed is broader with more potential applicability, while also coming from the same lead inventors and institution," said Anthony Hayes, CEO of Aikido."We will continue to investigate the technology covered by our option and we will be providing additional information about this antiviral platform...
The cruise industry received another blow on April 9, when the Centers for Disease Control and Prevention extended its initial No Sail Order a further 100 days, pushing the potential resumption of the cruise industry's operations until late July. But the cruise industry seems to think this rule doesn't yet apply to them just yet. […]...
European counties like Australia and Italy reopened thousands of shops, sending more people back to work and realizing on COVID restrictions. Yahoo Finance’s Tom Belger breaks down the latest developments....
Apr.14 -- Laszlo Birinyi, founder of Birinyi Associates, breaks down the trading activity in the S&P 500, General Motors Co., Exxon Mobil Corp., Tesla Inc. and Starbucks Corp. shares. He speaks with Bloomberg's Vonnie Quinn on "Bloomberg Markets."...
Gold markets spiked during the trading session on Tuesday, reaching close to the $1800 level, as the market started to focus on fear, and perhaps even the Federal Reserve. That being said, we gave up quite a bit of the gains midday, which of course is not a good sign....
Shares of Canadian cannabis company Aurora Cannabis (ACB) took another tumble on Monday. With its stock down 65% since the start of the year, and cash burn accelerating to an annualized pace of more than $600 million over the past year, patience seems to be draining out for investors.In a Form 6-K filing with the SEC, Aurora on Monday announced that after burning through much of the $400 million raised from "At-The-Market" (ATM) stock sales in 2019 (Aurora has about $205 million of that left), it is returning to the public markets with a new offering to sell stock and raise an additional $350 million "to provide further balance sheet strength and preserve flexibility given macroeconomic uncertainty caused by COVID-19."Aurora Cannabis stock promptly fell 13% to close the day at less than $0.76 per share -- which is understandable.After all, in order to raise the targeted $350 million, Aurora Cannabis will...
